Iambic Therapeutics, a biotech startup focused on AI-driven drug discovery, has filed an S-1 registration statement with the SEC for a Nasdaq IPO. The company, founded in 2019 as Entos, plans to trade under the ticker symbol IAM. It has secured approximately $461.8 million in total funding from investors including Catalio, Nexus Ventures, Coatue Management, and Q Healthcare Holding.
The company maintains a strategic technology partnership with Nvidia, which began during the Series B funding round. Nvidia provides hardware and software integration to optimize the Iambic drug discovery platform. Additionally, Iambic recently announced a collaboration with AbbVie to utilize AI for drug development purposes.
The clinical pipeline of the firm features IAM1363, a treatment for solid tumors, alongside programs IAM-H1 and IAM-C1. The IPO process is managed by underwriters including J.P. Morgan, Jefferies, BofA Securities, and Citigroup. The company has not yet disclosed the specific share price range or the total number of shares to be offered.
